Effect of drug interactions with apixaban on clinical outcomes in cancer patients with venous thromboembolism.

ABSTRACT:

Introduction

It is unclear how drug-interaction with apixaban influences recurrent venous thromboembolism (VTE) and bleedings in cancer patients.

Methods

A post-hoc analysis of a single-arm interventional clinical trial on apixaban treatment of cancer patients with VTE to investigate whether the occurrence of any of the endpoints could be associated with the concurrent use of an interacting drug. Drugs taken by the patients during the trial period were categorized as either increasing bleeding risk, increasing thrombosis risk, both or neither.

Results

298 patients were divided into groups based on whether they used no interacting drugs (controls, n=74), drugs increasing bleeding risk (n=55), drugs increasing thrombosis risk (n=8), or both (n=161). Odds ratios (

SUBMITTER: Svalastoga M 

PROVIDER: S-EPMC11807833 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature